This signal shows up early, even before symptoms appear ... There have even been cases where people developed type 1 diabetes after being treated with IFNα for hepatitis C or leukemia.

Shortly after ... before big pharma rivals got wind of the development, his team was able to put forward a potentially broad development plan that could include PsA, AS and HS as well as psoriasis.

Icotrokinra demonstrated high rates of clearance in scalp and genital psoriasis after 16 weeks of treatment, according to ...

Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body, the phase III ARRECTOR trial showed.

Johnson & Johnson (JNJ) posts promising late-stage trial data for plaque psoriasis icotrokinra developed with Protagonist ...

Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch ...

The Fallout TV series has already been renewed for a third season on Amazon Prime. That's despite the show's second season still being months away - and indeed, we now know Fallout's next batch of ...

“Some people have cracking of heels because they have a skin condition like foot fungus (tinea pedis), psoriasis or eczema ... Also, being more mindful to moisturize immediately after bathing, as well ...

47 Skin is the skincare brand taking over social media with customers sharing their amazing before and after results. Did you know with a Digital Subscription to The Scotsman, you can get ...

Brooks will have plenty of time to rehab before the 2026 season. Additionally, Carolina formally released edge rusher Jadeveon Clowney. The hometown prospect lead the team with 5.5 sacks last year.

The Arizona Diamondbacks have had mixed results to start the season, as their 21-20 record effectively demonstrates. They just split their latest four-game series against the Los Angeles Dodgers ...

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...